Biopharma Can Reduce the Cost of Bringing A Treatment to Market by More Than US$1 Billion, According to Accenture Report
Retrieved on:
火曜日, 10月 26, 2021
Software, Research, Networks, General Health, Professional Services, Pharmaceutical, Data Management, Technology, Science, Biotechnology, Consulting, Health, Science, Advanced technology, Research, Biotechnology, Technology, The New Science, Disease, Evaluation, Histology, Interactivity, Patient, Machine learning, NYSE, List of life sciences, Risk, Medicine, Biomarker, Operation, Signals intelligence operational platforms by nation, Digital, Culture, Fine chemical, Pharmaceutical industry, Medical imaging
A new report from Accenture (NYSE: ACN) identifies three steps biopharmaceutical organizations could take to reduce the average cost of discovering and developing a treatment by more than US$1 billion.
Key Points:
- A new report from Accenture (NYSE: ACN) identifies three steps biopharmaceutical organizations could take to reduce the average cost of discovering and developing a treatment by more than US$1 billion.
- Furthermore, it could potentially create additional future revenue opportunities of up to US$450 million per treatment.
- Greater R&D productivity notes that the cost of bringing a successful treatment to market is between US$2.6 billion and $6.7 billion, depending on therapeutic area, treatment modality and disease complexity.
- The healthcare ecosystem is under significant price pressure at both the system and patient levels.